EA202192405A1 - Составы антител против il-36r - Google Patents
Составы антител против il-36rInfo
- Publication number
- EA202192405A1 EA202192405A1 EA202192405A EA202192405A EA202192405A1 EA 202192405 A1 EA202192405 A1 EA 202192405A1 EA 202192405 A EA202192405 A EA 202192405A EA 202192405 A EA202192405 A EA 202192405A EA 202192405 A1 EA202192405 A1 EA 202192405A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- antibodies against
- administration
- subject
- relates
- Prior art date
Links
- 229940099539 IL-36 receptor antagonist Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000852965 Homo sapiens Interleukin-1 receptor-like 2 Proteins 0.000 title 1
- 102100036697 Interleukin-1 receptor-like 2 Human genes 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815405P | 2019-03-08 | 2019-03-08 | |
| PCT/US2020/021059 WO2020185479A1 (en) | 2019-03-08 | 2020-03-05 | Anti-il-36r antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192405A1 true EA202192405A1 (ru) | 2022-01-13 |
Family
ID=70009446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192405A EA202192405A1 (ru) | 2019-03-08 | 2020-03-05 | Составы антител против il-36r |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11730812B2 (enExample) |
| EP (1) | EP3934617A1 (enExample) |
| JP (2) | JP7420827B2 (enExample) |
| KR (1) | KR20210137520A (enExample) |
| CN (1) | CN113543772A (enExample) |
| AU (1) | AU2020238676B2 (enExample) |
| BR (1) | BR112021016198A2 (enExample) |
| CA (1) | CA3132917A1 (enExample) |
| CL (1) | CL2021002331A1 (enExample) |
| EA (1) | EA202192405A1 (enExample) |
| IL (1) | IL286100B2 (enExample) |
| MX (1) | MX2021010783A (enExample) |
| PH (1) | PH12021552150A1 (enExample) |
| TW (1) | TW202100141A (enExample) |
| WO (1) | WO2020185479A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6913026B2 (ja) | 2015-04-15 | 2021-08-04 | アナプティスバイオ インコーポレイティッド | インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 |
| US20190284273A1 (en) * | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| MX2021010783A (es) | 2019-03-08 | 2021-09-30 | Boehringer Ingelheim Int | Formulaciones de anticuerpo anti-il-36r. |
| JP2023534955A (ja) | 2020-07-17 | 2023-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体 |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| CN114907477A (zh) * | 2021-02-08 | 2022-08-16 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| EP4301409A1 (en) | 2021-03-04 | 2024-01-10 | Boehringer Ingelheim International GmbH | Methods for the treatment of gpp |
| KR20240021800A (ko) * | 2021-05-12 | 2024-02-19 | 아납티스바이오, 아이엔씨. | 항체 조성물 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| DE69836082T2 (de) | 1997-08-01 | 2007-05-10 | Schering Corp. | Membranproteine aus säugetierzellen; verwandte reagentien |
| US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| WO2004031362A2 (en) | 2002-10-03 | 2004-04-15 | Large Scale Biology Corporation | Multimeric protein engineering |
| HRP20050934B1 (hr) * | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AU2007294909A1 (en) | 2006-09-08 | 2008-03-20 | Amgen Inc. | IL-1 family variants |
| JP2010526066A (ja) | 2007-04-23 | 2010-07-29 | シェーリング コーポレイション | 抗ｍｄｌ−１抗体 |
| ES2540854T3 (es) | 2007-06-29 | 2015-07-14 | Merck Sharp & Dohme Corp. | Usos de antagonistas MDL-1 |
| US20110159011A1 (en) | 2008-08-28 | 2011-06-30 | Wyeth Llc | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| US20120121580A1 (en) * | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| EP2805731B1 (en) * | 2009-09-03 | 2018-10-31 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| EP2542221A4 (en) | 2010-03-01 | 2013-10-23 | Cytodyn Inc | CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF |
| SG11201402283PA (en) * | 2011-11-16 | 2014-06-27 | Boehringer Ingelheim Int | Anti il-36r antibodies |
| MY164611A (en) * | 2012-01-23 | 2018-01-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| CA2882771C (en) | 2012-08-24 | 2021-02-23 | Novartis Ag | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| WO2016128564A1 (en) | 2015-02-13 | 2016-08-18 | Sanofi | Stable liquid formulation for monoclonal antibodies |
| JP6913026B2 (ja) | 2015-04-15 | 2021-08-04 | アナプティスバイオ インコーポレイティッド | インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体 |
| CN107921967B (zh) | 2015-08-05 | 2021-06-01 | 福特全球技术公司 | 用于车辆的客户驾驶模式 |
| EP3601350A1 (en) | 2017-03-27 | 2020-02-05 | Boehringer Ingelheim International GmbH | Anti il-36r antibodies combination therapy |
| CN112272674A (zh) | 2018-03-14 | 2021-01-26 | 勃林格殷格翰国际有限公司 | 抗-il-36r抗体用于治疗泛发性脓疱性银屑病的用途 |
| US20190284273A1 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| JP2022515480A (ja) | 2018-12-27 | 2022-02-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体 |
| MX2021010783A (es) | 2019-03-08 | 2021-09-30 | Boehringer Ingelheim Int | Formulaciones de anticuerpo anti-il-36r. |
-
2020
- 2020-03-05 MX MX2021010783A patent/MX2021010783A/es unknown
- 2020-03-05 PH PH1/2021/552150A patent/PH12021552150A1/en unknown
- 2020-03-05 TW TW109107268A patent/TW202100141A/zh unknown
- 2020-03-05 EA EA202192405A patent/EA202192405A1/ru unknown
- 2020-03-05 BR BR112021016198A patent/BR112021016198A2/pt unknown
- 2020-03-05 CN CN202080019100.2A patent/CN113543772A/zh active Pending
- 2020-03-05 KR KR1020217032399A patent/KR20210137520A/ko active Pending
- 2020-03-05 IL IL286100A patent/IL286100B2/en unknown
- 2020-03-05 US US16/809,606 patent/US11730812B2/en active Active
- 2020-03-05 EP EP20714813.1A patent/EP3934617A1/en active Pending
- 2020-03-05 CA CA3132917A patent/CA3132917A1/en active Pending
- 2020-03-05 AU AU2020238676A patent/AU2020238676B2/en active Active
- 2020-03-05 WO PCT/US2020/021059 patent/WO2020185479A1/en not_active Ceased
- 2020-03-05 JP JP2021552832A patent/JP7420827B2/ja active Active
-
2021
- 2021-09-07 CL CL2021002331A patent/CL2021002331A1/es unknown
-
2023
- 2023-07-17 US US18/353,133 patent/US20230372480A1/en active Pending
- 2023-11-13 JP JP2023193220A patent/JP2024020372A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3934617A1 (en) | 2022-01-12 |
| CL2021002331A1 (es) | 2022-06-17 |
| PH12021552150A1 (en) | 2022-08-15 |
| TW202100141A (zh) | 2021-01-01 |
| IL286100B1 (en) | 2024-08-01 |
| CN113543772A (zh) | 2021-10-22 |
| IL286100A (en) | 2021-10-31 |
| JP2024020372A (ja) | 2024-02-14 |
| KR20210137520A (ko) | 2021-11-17 |
| MX2021010783A (es) | 2021-09-30 |
| WO2020185479A1 (en) | 2020-09-17 |
| AU2020238676A1 (en) | 2021-09-16 |
| US20230372480A1 (en) | 2023-11-23 |
| AU2020238676B2 (en) | 2025-04-17 |
| US11730812B2 (en) | 2023-08-22 |
| US20200282053A1 (en) | 2020-09-10 |
| JP2022524502A (ja) | 2022-05-06 |
| CA3132917A1 (en) | 2020-09-17 |
| JP7420827B2 (ja) | 2024-01-23 |
| BR112021016198A2 (pt) | 2021-11-03 |
| IL286100B2 (en) | 2024-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202192405A1 (ru) | Составы антител против il-36r | |
| EA201891694A1 (ru) | Фармацевтическая композиция, содержащая конструкты биспецифических антител | |
| CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
| CO2018013471A2 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco | |
| EA202190808A2 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| CY1124521T1 (el) | Σκευασματα αντισωματος anti-cd19 | |
| BR112018075630A2 (pt) | anticorpos anti-cd98 e conjugados de fármaco de anticorpo | |
| WO2019171253A8 (en) | Anti-pd-1 antibody compositions | |
| BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
| MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
| EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
| MX381232B (es) | Formulación de anticuerpos. | |
| MX2018015280A (es) | Conjugados de anticuerpo y farmaco anti-egfr. | |
| MX2017004975A (es) | Composiciones de anticuerpos anti-il-7r. | |
| EP3648801A4 (en) | RADIOIMMUNOTHERAPY DOTA HAPTEN COMPOSITIONS THAT TARGET A BISPECIFIC ANTI-DOTA / ANTI-TUMOR ANTIGEN ANTIBODY | |
| IL288153A (en) | Stabilized formulations containing anti-angptl3 antibodies | |
| EP3823978A4 (en) | Fcrn antibody compositions | |
| MX2020009149A (es) | Compuestos que incluyen una secuencia de kras mutante y un lipido y usos de los mismos. | |
| EP3995582A4 (en) | ANTI-EPHA4 ANTIBODIES | |
| IL281976A (en) | Anti-fgfr2 antibody formulations | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| CR20210200A (es) | Formulación de anticuerpos | |
| EA201992027A1 (ru) | Водный состав антитела против pd-l1 | |
| EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
| EP3432925A4 (en) | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY |